BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 15003892)

  • 1. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
    Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
    Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of osteopontin in adhesion, migration, cell survival and bone remodeling.
    Standal T; Borset M; Sundan A
    Exp Oncol; 2004 Sep; 26(3):179-84. PubMed ID: 15494684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model.
    Caers J; Günthert U; De Raeve H; Van Valckenborgh E; Menu E; Van Riet I; Van Camp B; Vanderkerken K
    Br J Haematol; 2006 Feb; 132(4):469-77. PubMed ID: 16412019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients.
    Colla S; Morandi F; Lazzaretti M; Rizzato R; Lunghi P; Bonomini S; Mancini C; Pedrazzoni M; Crugnola M; Rizzoli V; Giuliani N
    Leukemia; 2005 Dec; 19(12):2166-76. PubMed ID: 16208410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications.
    Saeki Y; Mima T; Ishii T; Ogata A; Kobayashi H; Ohshima S; Ishida T; Tabunoki Y; Kitayama H; Mizuki M; Katada Y; Asaoku H; Kitano M; Nishimoto N; Yoshizaki K; Maeda M; Kon S; Kinoshita N; Uede T; Kawase I
    Br J Haematol; 2003 Oct; 123(2):263-70. PubMed ID: 14531907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
    Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.
    Oates AJ; Barraclough R; Rudland PS
    Oncogene; 1996 Jul; 13(1):97-104. PubMed ID: 8700559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
    Chang PL; Chambers AF
    J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
    Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
    Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
    Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
    Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
    Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
    Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
    Koopmann J; Fedarko NS; Jain A; Maitra A; Iacobuzio-Donahue C; Rahman A; Hruban RH; Yeo CJ; Goggins M
    Cancer Epidemiol Biomarkers Prev; 2004 Mar; 13(3):487-91. PubMed ID: 15006928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells.
    Said HM; Katzer A; Flentje M; Vordermark D
    Radiother Oncol; 2005 Aug; 76(2):200-5. PubMed ID: 16024111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
    Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
    Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
    Mi Z; Guo H; Wai PY; Gao C; Kuo PC
    Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin dysregulation and lytic bone lesions in multiple myeloma.
    Robbiani DF; Colon K; Ely S; Ely S; Chesi M; Bergsagel PL
    Hematol Oncol; 2007 Mar; 25(1):16-20. PubMed ID: 17044113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
    Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
    Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
    Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
    Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.
    Westendorf JJ; Ahmann GJ; Armitage RJ; Spriggs MK; Lust JA; Greipp PR; Katzmann JA; Jelinek DF
    J Immunol; 1994 Jan; 152(1):117-28. PubMed ID: 7504707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.